Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company offers cerebrum, a small molecule platform for CNS small molecule therapies and solidus, an antisense oligonucleotide platform to discover and develop antisense oligonucleotide. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020; and PRAX-050. In addition, the company develops elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080; PRAX-090; and PRAX-100. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Praxis Precision Medicines Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oruka Therapeutics (ORKA) and Praxis Precision Medic...

Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA) and Praxis Precision Medicines (PRAX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Molina Healthcare (MOH), Boston Scientific (BSX) a...

Analysts Conflicted on These Healthcare Names: Molina Healthcare (MOH), Boston Scientific (BSX) and Praxis Precision Medicines (PRAX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Praxis Precision Medicines (PRAX), Spyre Therapeutic...

Analysts Are Bullish on These Healthcare Stocks: Praxis Precision Medicines (PRAX), Spyre Therapeutics (SYRE)

Praxis Precision Medicines ( ($PRAX) ) has shared an update. On April 14, 2026, Praxis Precision Medicines, Inc. announced that the U.S. Food and D...

Praxis Precision NDA for Ulixacaltamide in Essential Tremor

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Exelixis (EXEL) and Praxis Precision Medicines (PRAX...

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Praxis Precision Medicines (PRAX), Oncology Institut...

Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), Oncology Institute (TOI)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on PDS Biotechnology (PDSB), Eli Lilly & Co (LLY) and P...

Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Eli Lilly & Co (LLY) and Praxis Precision Medicines (PRAX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Praxis Precision Medicines (PRAX), PepGen Inc. (PE...

Current Quarter	$-3.58	Next Quarter	$-3.72
Current Year	$-14.88	Next Year	$-9.84
QoQ Growth	-3.9%	YoY Growth	+33.9%
3Y EPS CAGR	+42.1%	Target Price	$614.61
Consensus	Buy	Upside	+78.2%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PRAX	$344.82	+4.62%	345.88K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PRAX	$344.82	+4.6%	345.88K
3
4
5
6

PRAX

PRAX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Praxis Precision Medicines Inc. Data in Excel

Get Praxis Precision Medicines Inc. Data in Excel